RxDoctor Payments Data

Fernando Rodriguez, MD

Nephrology · Tampa, FLNPI 1962425165

Payments from drug & device makers

$1,935in general payments, 2019–2025

Across 21 payments — averaging $92.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$631
  • Amgen$546
  • AstraZeneca$242
  • Travere Therapeutics, Inc.$226
  • Mallinckrodt Hospital Products Inc.$156
  • Aurinia Pharma U.S., Inc.$111
  • plus $24 from 1 others

What the payments were for

  • Food & beverage$1,81194%
  • Education$1236%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,935 in reported general payments places this provider in the 50th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$51,169
Medicare patients
78
Services billed
533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol188$155,451
KerendiaFinerenone137$133,503
JardianceEmpagliflozin85$63,306
VeltassaPatiromer Calcium Sorbitex24$15,536
Sevelamer Carbonate51$8,601
InvokanaCanagliflozin12$6,901
LokelmaSodium Zirconium Cyclosilicate12$4,419
Calcitriol194$2,543
Calcium Acetate26$1,169
Nifedipine ErNifedipine21$747
Hydralazine Hcl31$525
Potassium Chloride11$234
Losartan Potassium28$199
Famotidine16$198
Allopurinol31$178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$242$159,870200 claims
BayerKerendia$631$133,503137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 756 nephrology providers in Florida.

Other nephrology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →